ALK and non-small cell lung carcinoma: The phase 1b JAVELIN 101 Lung trial evaluated the second-line combination of avelumab and crizotinib in ALK-negative NSCLC patients, and 2 out of 12 patients (16.7%) had dose-limiting hepatotoxicity.